NASDAQ:AMAG - AMAG Pharmaceuticals Stock Price, Price Target & More

$19.70 +0.35 (+1.81 %)
(As of 04/23/2018 04:00 PM ET)
Previous Close$19.70
Today's Range$19.00 - $19.70
52-Week Range$11.93 - $24.85
Volume604,875 shs
Average Volume1.14 million shs
Market Capitalization$659.62 million
P/E Ratio-3.45
Dividend YieldN/A
Beta0.09

About AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals logoAMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has an option agreement with Velo Bio LLC to acquire the rights to digoxin immune fab, a polyclonal antibody, which is in Phase IIb/IIIa trial for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Bremelanotide, an investigational product for the treatment of hypoactive sexual desire disorder (HSDD) in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, offer for sale, and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

Receive AMAG News and Ratings via Email

Sign-up to receive the latest news and ratings for AMAG and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMAG
CUSIP00163U10
Phone617-498-3300

Debt

Debt-to-Equity Ratio0.93%
Current Ratio1.74%
Quick Ratio1.60%

Price-To-Earnings

Trailing P/E Ratio-3.45
Forward P/E Ratio-6.06
P/E GrowthN/A

Sales & Book Value

Annual Sales$609.95 million
Price / Sales1.10
Cash FlowN/A
Price / CashN/A
Book Value$22.34 per share
Price / Book0.88

Profitability

EPS (Most Recent Fiscal Year)($5.71)
Net Income$-199,220,000.00
Net Margins-32.66%
Return on Equity0.96%
Return on Assets0.39%

Miscellaneous

Employees762
Outstanding Shares34,090,000

How to Become a New Pot Stock Millionaire

AMAG Pharmaceuticals (NASDAQ:AMAG) Frequently Asked Questions

What is AMAG Pharmaceuticals' stock symbol?

AMAG Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMAG."

How were AMAG Pharmaceuticals' earnings last quarter?

AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced its earnings results on Tuesday, February, 27th. The specialty pharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.68. The specialty pharmaceutical company had revenue of $158.30 million for the quarter, compared to analysts' expectations of $158.84 million. AMAG Pharmaceuticals had a positive return on equity of 0.96% and a negative net margin of 32.66%. The business's revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter last year, the firm earned ($0.31) EPS. View AMAG Pharmaceuticals' Earnings History.

When is AMAG Pharmaceuticals' next earnings date?

AMAG Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for AMAG Pharmaceuticals.

What price target have analysts set for AMAG?

11 analysts have issued 1 year target prices for AMAG Pharmaceuticals' stock. Their forecasts range from $17.00 to $45.00. On average, they expect AMAG Pharmaceuticals' stock price to reach $24.20 in the next year. View Analyst Ratings for AMAG Pharmaceuticals.

What are Wall Street analysts saying about AMAG Pharmaceuticals stock?

Here are some recent quotes from research analysts about AMAG Pharmaceuticals stock:
  • 1. Cantor Fitzgerald analysts commented, "Makena autoinjector moving to launch pad. On today’s call, management commented that the autoinjector would be launched by the end of March. Pre- launch activities include the critical element of providing patient access to the drug. We believe it possible that the switch to the autoinjector could be facilitated through modulating the Makena vial (IM administration) inventory." (2/27/2018)
  • 2. According to Zacks Investment Research, "AMAG reported earnings of $1.57 in the third quarter of 2017 as against the Zacks Consensus Estimate of a loss. However, the company missed the same on revenues. AMAG lowered its total revenue guidance for 2017. Furthermore, the termination of the licensing agreement with Takeda for Feraheme in ex-U.S. territories was a major setback for the company. So far this year, AMAG’s shares have underperformed the industry.  Nevertheless, the company  is working towards label expansion of Feraheme, and potential approval and launch of the Makena subcutaneous auto-injector (SQ) AMAG also remains focused on expanding Makena’s label further in a bid to increase its market share." (11/8/2017)

Who are some of AMAG Pharmaceuticals' key competitors?

Who are AMAG Pharmaceuticals' key executives?

AMAG Pharmaceuticals' management team includes the folowing people:
  • Dr. William K. Heiden, CEO & Director (Age 58)
  • Mr. Edward H. Myles MBA, Exec. VP & CFO (Age 46)
  • Mr. Joseph D. Vittiglio Esq., Exec. VP of Quality, Gen. Counsel & Sec. (Age 46)
  • Dr. Julie Krop M.D., Exec. VP & Chief Medical Officer (Age 52)
  • Mr. Nicholas Grund, Exec. VP & Chief Commercial Officer (Age 48)

Has AMAG Pharmaceuticals been receiving favorable news coverage?

News coverage about AMAG stock has been trending somewhat positive this week, Accern reports. The research group identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a news sentiment score of 0.12 on Accern's scale. They also gave news stories about the specialty pharmaceutical company an impact score of 45.99 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

How do I buy shares of AMAG Pharmaceuticals?

Shares of AMAG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AMAG Pharmaceuticals' stock price today?

One share of AMAG stock can currently be purchased for approximately $19.70.

How big of a company is AMAG Pharmaceuticals?

AMAG Pharmaceuticals has a market capitalization of $659.62 million and generates $609.95 million in revenue each year. The specialty pharmaceutical company earns $-199,220,000.00 in net income (profit) each year or ($5.71) on an earnings per share basis. AMAG Pharmaceuticals employs 762 workers across the globe.

How can I contact AMAG Pharmaceuticals?

AMAG Pharmaceuticals' mailing address is 1100 WINTER STREET, WALTHAM MA, 02451. The specialty pharmaceutical company can be reached via phone at 617-498-3300 or via email at [email protected]


MarketBeat Community Rating for AMAG Pharmaceuticals (AMAG)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  272 (Vote Outperform)
Underperform Votes:  354 (Vote Underperform)
Total Votes:  626
MarketBeat's community ratings are surveys of what our community members think about AMAG Pharmaceuticals and other stocks. Vote "Outperform" if you believe AMAG will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMAG will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

AMAG Pharmaceuticals (NASDAQ:AMAG) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
11 Wall Street analysts have issued ratings and price targets for AMAG Pharmaceuticals in the last 12 months. Their average twelve-month price target is $24.20, suggesting that the stock has a possible upside of 22.84%. The high price target for AMAG is $45.00 and the low price target for AMAG is $17.00. There are currently 9 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.182.182.252.14
Ratings Breakdown: 0 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
10 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $24.20$24.20$21.00$27.4167
Price Target Upside: 22.84% upside20.40% upside58.49% upside75.75% upside

AMAG Pharmaceuticals (NASDAQ:AMAG) Consensus Price Target History

Price Target History for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/14/2018B. RileyBoost Price TargetNeutral -> Neutral$16.00 -> $23.00MediumView Rating Details
3/5/2018Jefferies GroupDowngradeBuy -> Hold$21.00 -> $20.00LowView Rating Details
3/1/2018Piper JaffrayReiterated RatingHold$20.00MediumView Rating Details
2/28/2018Morgan StanleyBoost Price TargetOverweight -> Overweight$22.00 -> $24.00MediumView Rating Details
2/27/2018CowenReiterated RatingHold$25.00MediumView Rating Details
2/27/2018Cantor FitzgeraldReiterated RatingHold$17.00MediumView Rating Details
2/15/2018Janney Montgomery ScottUpgradeNeutral -> Buy$16.65 -> $45.00HighView Rating Details
2/2/2018Leerink SwannReiterated RatingMarket PerformHighView Rating Details
8/31/2017Deutsche BankReiterated RatingHold$24.00LowView Rating Details
7/7/2017CitigroupLower Price TargetHold$24.00LowView Rating Details
6/1/2017BarclaysReiterated RatingEqual Weight$25.00 -> $20.00LowView Rating Details
2/2/2017GuggenheimLower Price TargetBuy$42.00 -> $28.00N/AView Rating Details
1/31/2017JPMorgan ChaseSet Price TargetHold$24.00N/AView Rating Details
1/11/2017Needham & Company LLCDowngradeBuy -> HoldN/AView Rating Details
1/9/2017Raymond JamesReiterated RatingMarket Perform -> UnderperformN/AView Rating Details
(Data available from 4/23/2016 forward)

Earnings

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings History and Estimates Chart

Earnings by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ:AMAG) Earnings Estimates

2018 EPS Consensus Estimate: ($3.97)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.80)($0.08)($0.35)
Q2 20182($0.68)($0.02)($0.35)
Q3 20182($2.13)($0.57)($1.35)
Q4 20182($2.40)($1.44)($1.92)

AMAG Pharmaceuticals (NASDAQ AMAG) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/30/2018($0.24)N/AView Earnings Details
2/27/2018Q4 2017($0.58)$0.10$158.84 million$158.30 millionViewN/AView Earnings Details
11/2/2017Q3 2017($0.04)$1.57$166.83 million$153.74 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.58)($0.40)$158.83 million$158.39 millionViewListenView Earnings Details
5/2/2017Q1 2017$0.09($1.06)$150.32 million$139.47 millionViewListenView Earnings Details
2/14/2017Q416$0.24($0.31)$155.12 million$151.60 millionViewListenView Earnings Details
11/3/2016Q316$1.50$1.78$141.65 million$143.80 millionViewListenView Earnings Details
8/9/2016Q216$1.20$1.45$128.52 million$127.40 millionViewListenView Earnings Details
5/3/2016Q116$1.11$0.94$124.83 million$117.60 millionViewListenView Earnings Details
2/17/2016Q415$1.16$1.12$120.13 million$108.70 millionViewListenView Earnings Details
11/3/2015Q315$1.21($0.62)$113.88 million$103.50 millionViewListenView Earnings Details
7/23/2015Q215$0.75$1.12$94.05 million$123.90 millionViewListenView Earnings Details
5/5/2015Q115$1.04$1.11$84.66 million$89.50 millionViewListenView Earnings Details
2/9/2015Q4 2014$0.30$0.04$53.94 million$53.25 millionViewN/AView Earnings Details
10/30/2014Q314($0.08)$0.06$26.30 million$25.50 millionViewListenView Earnings Details
7/29/2014Q214($0.09)($0.07)$23.40 million$24.80 millionViewListenView Earnings Details
4/24/2014Q1($0.07)($0.33)$22.73 million$20.80 millionViewListenView Earnings Details
2/6/2014Q4($0.10)($0.17)$21.01 million$21.70 millionViewListenView Earnings Details
10/17/2013Q313($0.12)($0.01)$20.37 million$21.60 millionViewListenView Earnings Details
8/1/2013Q2 2013($0.17)($0.09)$18.51 million$19.60 millionViewListenView Earnings Details
4/23/2013Q1 2013($0.20)($0.18)$17.99 million$17.90 millionViewListenView Earnings Details
3/1/2013Q4 2012($0.06)($0.17)$22.54 million$21.14 millionViewN/AView Earnings Details
11/1/2012Q312($0.26)($0.19)$20.43 million$17.70 millionViewN/AView Earnings Details
7/26/2012($0.39)$0.16ViewN/AView Earnings Details
5/1/2012($0.63)($0.58)ViewN/AView Earnings Details
3/5/2012($1.09)($0.87)ViewN/AView Earnings Details
11/4/2011($0.98)($0.78)ViewN/AView Earnings Details
7/26/2011Q2 2011($1.08)($0.92)ViewN/AView Earnings Details
5/3/2011($0.99)($1.05)ViewN/AView Earnings Details
2/25/2011($1.04)($0.94)ViewN/AView Earnings Details
10/28/2010Q3 2010($1.09)($0.81)ViewN/AView Earnings Details
7/28/2010Q2 2010($0.97)($1.02)ViewN/AView Earnings Details
4/27/2010Q1 2010($0.84)($1.15)ViewN/AView Earnings Details
3/1/2010Q4 2009($1.08)($1.07)ViewN/AView Earnings Details
10/29/2009Q3 2009($1.45)($1.29)ViewN/AView Earnings Details
7/29/2009Q2 2009($1.53)($1.55)ViewN/AView Earnings Details
4/30/2009Q1 2009($1.30)($1.55)ViewN/AView Earnings Details
2/27/2009Q4 2008($1.40)($1.28)ViewN/AView Earnings Details
11/3/2008Q3 2008($1.12)($1.39)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.62)($1.00)ViewN/AView Earnings Details
4/25/2008Q1 2008($0.60)($0.55)ViewN/AView Earnings Details
2/21/2008Q4 2007($0.53)($0.57)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

AMAG Pharmaceuticals (NASDAQ:AMAG) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.80%
Insider Trading History for AMAG Pharmaceuticals (NASDAQ:AMAG)
Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

AMAG Pharmaceuticals (NASDAQ AMAG) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Joseph VittiglioEVPSell770$20.80$16,016.0032,635View SEC Filing  
8/29/2017Joseph VittiglioSVPSell1,250$16.75$20,937.5033,504View SEC Filing  
7/13/2017Julie KropSVPSell4,938$20.00$98,760.0028,336View SEC Filing  
5/1/2017Julie KropSVPSell1,891$24.45$46,234.9536,777View SEC Filing  
10/20/2016Julie KropSVPSell4,938$24.80$122,462.4023,668View SEC Filing  
11/10/2015John A FallonDirectorBuy3,230$31.20$100,776.006,086View SEC Filing  
10/1/2015William K HeidenCEOSell2,000$39.69$79,380.00200,721View SEC Filing  
9/1/2015William K HeidenCEOSell2,000$61.19$122,380.00202,721View SEC Filing  
7/15/2015William K HeidenCEOSell20,000$75.00$1,500,000.00View SEC Filing  
6/15/2015Scott A HolmesSVPSell7,580$66.63$505,055.40View SEC Filing  
6/5/2015William K HeidenCEOSell66,875$69.90$4,674,562.50View SEC Filing  
6/4/2015Frank E ThomasCOOSell20,000$69.47$1,389,400.00View SEC Filing  
6/3/2015Scott A HolmesSVPSell22,516$68.88$1,550,902.08View SEC Filing  
1/9/2015Adage Capital Partners Gp LlcMajor ShareholderSell1,250,000$46.49$58,112,500.00View SEC Filing  
1/9/2014Christopher WhiteInsiderSell4,000$22.37$89,480.0024,834View SEC Filing  
1/7/2014Christopher WhiteInsiderSell5,000$23.90$119,500.0028,834View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

AMAG Pharmaceuticals (NASDAQ AMAG) News Headlines

Source:
DateHeadline
AMAG Pharmaceuticals (AMAG) to Release Quarterly Earnings on MondayAMAG Pharmaceuticals (AMAG) to Release Quarterly Earnings on Monday
www.americanbankingnews.com - April 23 at 7:14 AM
AMAG Pharmaceuticals (AMAG) Downgraded by BidaskClubAMAG Pharmaceuticals (AMAG) Downgraded by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
$155.89 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter$155.89 Million in Sales Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - April 17 at 3:44 AM
AMAG Pharmaceuticals, Inc. Expected to Post FY2020 Earnings of ($1.47) Per Share (AMAG)AMAG Pharmaceuticals, Inc. Expected to Post FY2020 Earnings of ($1.47) Per Share (AMAG)
www.americanbankingnews.com - April 16 at 3:03 AM
AMAG Pharmaceuticals (AMAG) Upgraded to Sell at ValuEngineAMAG Pharmaceuticals (AMAG) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - April 16 at 12:19 AM
-$0.48 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter-$0.48 EPS Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - April 15 at 11:11 AM
Edited Transcript of AMAG presentation 8-Mar-17 3:25pm GMTEdited Transcript of AMAG presentation 8-Mar-17 3:25pm GMT
finance.yahoo.com - April 12 at 5:44 PM
AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by AnalystsAMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 12 at 1:43 PM
AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by BidaskClubAMAG Pharmaceuticals (AMAG) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 10 at 10:30 PM
Reader Inquiry: Antares Pharma PDUFA Date In September, Is The Stock A Buy Here?Reader Inquiry: Antares Pharma PDUFA Date In September, Is The Stock A Buy Here?
seekingalpha.com - April 10 at 8:18 AM
Janney Montgomery Scott Reaffirms Hold Rating for AMAG Pharmaceuticals (AMAG)Janney Montgomery Scott Reaffirms Hold Rating for AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - April 6 at 10:54 PM
AMAG Pharmaceuticals (AMAG) Downgraded to Hold at Zacks Investment ResearchAMAG Pharmaceuticals (AMAG) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 6 at 9:16 PM
AMAG Pharmaceuticals (AMAG) Upgraded to Buy by BidaskClubAMAG Pharmaceuticals (AMAG) Upgraded to Buy by BidaskClub
www.americanbankingnews.com - April 6 at 11:59 AM
AMAG Pharmaceuticals (AMAG) Earns Neutral Rating from Analysts at Piper JaffrayAMAG Pharmaceuticals (AMAG) Earns Neutral Rating from Analysts at Piper Jaffray
www.americanbankingnews.com - April 6 at 11:31 AM
AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by Zacks Investment ResearchAMAG Pharmaceuticals (AMAG) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 5 at 7:58 PM
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory AffairsCRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs
globenewswire.com - April 4 at 4:19 PM
AMAG Pharmaceuticals (AMAG) Upgraded to "Hold" at Zacks Investment ResearchAMAG Pharmaceuticals (AMAG) Upgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - April 1 at 12:40 AM
AMAG Pharmaceuticals (AMAG) Lifted to Hold at ValuEngineAMAG Pharmaceuticals (AMAG) Lifted to Hold at ValuEngine
www.americanbankingnews.com - March 31 at 1:05 PM
AMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $155.89 MillionAMAG Pharmaceuticals, Inc. (AMAG) Expected to Announce Quarterly Sales of $155.89 Million
www.americanbankingnews.com - March 31 at 2:44 AM
AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?AMAG Pharma (AMAG) Down 10.6% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 29 at 5:35 PM
Zacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) to Post -$0.48 Earnings Per ShareZacks: Brokerages Anticipate AMAG Pharmaceuticals, Inc. (AMAG) to Post -$0.48 Earnings Per Share
www.americanbankingnews.com - March 29 at 3:14 PM
AMAG Pharmaceuticals (AMAG) Presents At Needham And Company 17th Annual Healthcare Conference - SlideshowAMAG Pharmaceuticals (AMAG) Presents At Needham And Company 17th Annual Healthcare Conference - Slideshow
seekingalpha.com - March 29 at 8:19 AM
B. Riley Reiterates Hold Rating for AMAG Pharmaceuticals (AMAG)B. Riley Reiterates Hold Rating for AMAG Pharmaceuticals (AMAG)
www.americanbankingnews.com - March 28 at 12:58 PM
BRIEF-AMAG Pharmaceuticals Submits NDA To FDA For BremelanotideBRIEF-AMAG Pharmaceuticals Submits NDA To FDA For Bremelanotide
www.reuters.com - March 27 at 5:19 PM
AMAG Pharma files U.S. marketing application for HSDD med bremelanotideAMAG Pharma files U.S. marketing application for HSDD med bremelanotide
seekingalpha.com - March 27 at 5:19 PM
AMAG Pharmaceuticals (AMAG) Upgraded to Sell at BidaskClubAMAG Pharmaceuticals (AMAG) Upgraded to Sell at BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
AMAG Pharma (AMAG) Submits NDA to FDA for Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder ...AMAG Pharma (AMAG) Submits NDA to FDA for Bremelanotide for Treatment of Hypoactive Sexual Desire Disorder ...
www.streetinsider.com - March 26 at 5:24 PM
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire ...Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire ...
www.prnewswire.com - March 26 at 5:24 PM
AMAG Pharmaceuticals Submits a New Drug Application to the US Food and Drug Administration for Bremelanotide for ...AMAG Pharmaceuticals Submits a New Drug Application to the US Food and Drug Administration for Bremelanotide for ...
globenewswire.com - March 26 at 5:24 PM
Palatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal WomenPalatin Technologies Announces Submission of Bremelanotide NDA to FDA for Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
finance.yahoo.com - March 26 at 8:16 AM
AMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal WomenAMAG Pharmaceuticals Submits a New Drug Application to the U.S. Food and Drug Administration for Bremelanotide for the treatment of Hypoactive Sexual Desire Disorder (HSDD) in Premenopausal Women
finance.yahoo.com - March 26 at 8:16 AM
AMAG Pharmaceuticals (AMAG) Stock Rating Lowered by ValuEngineAMAG Pharmaceuticals (AMAG) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - March 25 at 9:16 PM
AMAG Pharmaceuticals (AMAG) Upgraded by ValuEngine to "Hold"AMAG Pharmaceuticals (AMAG) Upgraded by ValuEngine to "Hold"
www.americanbankingnews.com - March 24 at 8:54 PM
Form 8-K AMAG PHARMACEUTICALS For: Mar 23Form 8-K AMAG PHARMACEUTICALS For: Mar 23
www.streetinsider.com - March 24 at 5:20 PM
Form 8-K AMAG PHARMACEUTICALS For: Mar 23 - StreetInsider.comForm 8-K AMAG PHARMACEUTICALS For: Mar 23 - StreetInsider.com
www.streetinsider.com - March 24 at 8:44 AM
AMAG Pharmaceuticals Target of Unusually High Options Trading (AMAG)AMAG Pharmaceuticals Target of Unusually High Options Trading (AMAG)
www.americanbankingnews.com - March 23 at 7:08 AM
AMAG Pharmaceuticals, Inc. (AMAG) Given Average Recommendation of "Hold" by BrokeragesAMAG Pharmaceuticals, Inc. (AMAG) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 18 at 1:50 PM
AMAG Pharmaceuticals, Inc. (AMAG) Forecasted to Earn Q1 2018 Earnings of ($0.18) Per ShareAMAG Pharmaceuticals, Inc. (AMAG) Forecasted to Earn Q1 2018 Earnings of ($0.18) Per Share
www.americanbankingnews.com - March 16 at 8:52 AM
AMAG Pharmaceuticals (AMAG) PT Raised to $23.00AMAG Pharmaceuticals (AMAG) PT Raised to $23.00
www.americanbankingnews.com - March 14 at 5:27 PM
Autodesk, SCANA, And 3 Other Stocks With Clear Trading Opportunities This WeekAutodesk, SCANA, And 3 Other Stocks With Clear Trading Opportunities This Week
www.benzinga.com - March 13 at 7:23 PM
-$0.58 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter-$0.58 Earnings Per Share Expected for AMAG Pharmaceuticals, Inc. (AMAG) This Quarter
www.americanbankingnews.com - March 12 at 1:44 PM
AMAG Pharmaceuticals (AMAG) Cut to Hold at BidaskClubAMAG Pharmaceuticals (AMAG) Cut to Hold at BidaskClub
www.americanbankingnews.com - March 10 at 9:45 AM
Form 4 AMAG PHARMACEUTICALS For: Mar 02 Filed by: Bolgiano Elizabeth ScottForm 4 AMAG PHARMACEUTICALS For: Mar 02 Filed by: Bolgiano Elizabeth Scott
www.streetinsider.com - March 7 at 6:40 PM
AMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Q1 2018 Earnings of ($0.08) Per ShareAMAG Pharmaceuticals, Inc. (AMAG) Expected to Post Q1 2018 Earnings of ($0.08) Per Share
www.americanbankingnews.com - March 7 at 8:16 AM
Antares Pharma: Building Momentum To 2018 Profitability - Antares ... - Seeking AlphaAntares Pharma: Building Momentum To 2018 Profitability - Antares ... - Seeking Alpha
seekingalpha.com - March 7 at 8:11 AM
AMAG Pharmaceuticals, Inc. (AMAG) EVP Joseph Vittiglio Sells 770 SharesAMAG Pharmaceuticals, Inc. (AMAG) EVP Joseph Vittiglio Sells 770 Shares
www.americanbankingnews.com - March 6 at 9:58 PM
Premarket analyst action - healthcare - AMAG Pharmaceuticals, Inc ... - Seeking AlphaPremarket analyst action - healthcare - AMAG Pharmaceuticals, Inc ... - Seeking Alpha
seekingalpha.com - March 6 at 8:10 AM
Jefferies Group Lowers AMAG Pharmaceuticals (AMAG) to HoldJefferies Group Lowers AMAG Pharmaceuticals (AMAG) to Hold
www.americanbankingnews.com - March 5 at 5:34 PM
AMAG Pharmaceuticals to Present at Upcoming Investor ConferencesAMAG Pharmaceuticals to Present at Upcoming Investor Conferences
finance.yahoo.com - March 5 at 8:12 AM
Bogle Investment Management L P DE Acquires Shares of 328,455 AMAG Pharmaceuticals, Inc. (AMAG)Bogle Investment Management L P DE Acquires Shares of 328,455 AMAG Pharmaceuticals, Inc. (AMAG)
www.americanbankingnews.com - March 4 at 4:58 AM

SEC Filings

AMAG Pharmaceuticals (NASDAQ:AMAG) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

AMAG Pharmaceuticals (NASDAQ:AMAG) Income Statement, Balance Sheet and Cash Flow Statement

Chart

AMAG Pharmaceuticals (NASDAQ AMAG) Stock Chart for Monday, April, 23, 2018

Loading chart…

This page was last updated on 4/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.